JAK-1 Inhibitor Filgotinib Efficacious, Safe for Rheumatoid Arthritis in Phase IIa Trial
The selective Janus kinase-1 inhibitor filgotinib has shown initial efficacy and adequate safety for the treatment of rheumatoid arthritis.
The selective Janus kinase-1 inhibitor filgotinib has shown initial efficacy and adequate safety for the treatment of rheumatoid arthritis.